Acute Myeloid Leukemia: Reviewing Current Best Practice and Exploring Novel Paradigms Ahead

Get up to date on the latest strategies for AML risk stratification optimal therapy selection based on molecular profiling and management of AML after induction therapy in the absence of hematopoietic stem cell transplant with downloadble slides from a live satellite symposium at ASH 2022 and an expert commentary.

Share

Program Content

Activities

FAQ: AML Treatment Strategies
AML Current Treatment Strategies and Paradigms Ahead: Expert Discussion of Frequently Asked Questions
Clinical Thought
Congratulations: You achieved a completion on 04/09/2022

Released: January 24, 2023

Expires: January 23, 2024

Activities

Tx for AML Without Biomarkers
Updated AML Classifications and Selecting Therapy for AML Without Actionable Alterations
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 09, 2022

Expires: December 08, 2023

Tx for AML With Biomarkers
Selecting Therapy for AML With Predictive Biomarkers or Actionable Alterations
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 09, 2022

Expires: December 08, 2023

Clinical Trials and Future Directions
Clinical Trial Spotlight and Future Directions
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 09, 2022

Expires: December 08, 2023

Faculty

cover img faculity

Courtney DiNardo, MD, MSCE

Professor of Medicine
Department of Leukemia
University of Texas MD Anderson Cancer Center
Houston, Texas

cover img faculity

Daniel A. Pollyea, MD, MS

Professor of Medicine
Clinical Director of Leukemia Services
Associate Chief of Clinical Affairs
Robert H. Allen MD Chair in Hematology Research
Division of Hematology
University of Colorado School of Medicine
Aurora, Colorado

cover img faculity

Eytan M. Stein, MD

Chief, Leukemia Service
Director, Program for Drug Development in Leukemia
Memorial Sloan Kettering Cancer Center
New York, New York

Provided by

ProCE Banner

Provided by the National Comprehensive Cancer Network in collaboration with Clinical Care Options, LLC

Supporters

Supported by educational grants from

Astellas Text

Daiichi Sankyo, Inc.

Gilead Sciences, Inc.

Servier Pharmaceuticals

Syndax

Partners

Clinical Care Options, LLC

ProCE Banner